nach oben

Tumor Biology

Erschienen in:

01.11.2015 | Research Article

MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression

verfasst von: Jianting Long, Caiwen Ou, Haoming Xia, Yifan Zhu, Dayue Liu

Erschienen in: Tumor Biology | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is one of the most common malignancies and a major cause of cancer-related mortality all over the world. A growing body of reports revealed that microRNAs play essential roles in the progression of cancers. Aberrant expression of miR-503 has been reported in several kinds of cancer. The aim of the current study was to elucidate the role of miR-503 in the pathogenesis of breast cancer. In the present study, our results suggested that miR-503 expression was markedly downregulated in breast cancer tissues and cells. Overexpression of miR-503 in breast cancer cell lines reduced cell proliferation through inducing G₀/G₁ cell cycle arrest by targeting CCND1. Together, our findings provide new knowledge regarding the role of miR-503 in the progression of breast cancer and indicate the role of miR-503 as a tumor suppressor microRNA (miRNA) in breast cancer.

Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. CA: Cancer J Clin. 2014;64:104–17.

Park YH, Lee SJ, Jung HA, Kim SM, Kim MJ, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH. Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: single institutional experience in Korea. Breast (Edinburgh, Scotland) 2015.

Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689–99.CrossRefPubMed

Brandt J, Garne JP, Tengrup I, Manjer J. Age at diagnosis in relation to survival following breast cancer: a cohort study. World J Surg Oncol. 2015;13:429.CrossRef

Migliaccio I, Malorni L, Hart CD, Guarducci C, Di Leo A. Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Med. 2015;13:280.CrossRef

Chai J, Wang S, Han D, Dong W, Xie C, Guo H. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2015;36:1313–21.CrossRef

Feng S, Pan W, Jin Y, Zheng J. Mir-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35:12339–44.CrossRef

Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518:107–10.CrossRefPubMed

Dalmay T. Mechanism of miRNA-mediated repression of mRNA translation. Essays Biochem. 2013;54:29–38.CrossRefPubMed

10.

van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011;11:644–56.CrossRefPubMed

11.

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.CrossRefPubMed

12.

Shen S, Yue H, Li Y, Qin J, Li K, Liu Y, et al. Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35:631–40.CrossRef

13.

Hao Z, Yang J, Wang C, Li Y, Zhang Y, Dong X, et al. MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer. Int J Clin Exp Med. 2015;8:480–7.PubMedPubMedCentral

14.

Sun B, Yang M, Li M, Wang F. The microRNA-217 functions as a tumor suppressor and is frequently downregulated in human osteosarcoma. Biomed Pharmacother = Biomed Pharmacotherapie. 2015;71:58–63.CrossRef

15.

Sun Q, Zhao X, Liu X, Wang Y, Huang J, Jiang B, et al. Mir-146a functions as a tumor suppressor in prostate cancer by targeting Rac1. Prostate. 2014;74:1613–21.CrossRefPubMed

16.

Chong Y, Zhang J, Guo X, Li G, Zhang S, Li C, et al. MicroRNA-503 acts as a tumor suppressor in osteosarcoma by targeting L1CAM. PLoS One. 2014;9, e114585.CrossRefPubMedPubMedCentral

17.

Wang T, Ge G, Ding Y, Zhou X, Huang Z, Zhu W, et al. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J. 2014;127:2357–62.PubMed

18.

Polioudakis D, Abell NS, Iyer VR. miR-503 represses human cell proliferation and directly targets the oncogene DDHD2 by non-canonical target pairing. BMC Genomics. 2015;16:40.CrossRefPubMedPubMedCentral

19.

Ruiz-Llorente L, Ardila-Gonzalez S, Fanjul LF, Martinez-Iglesias O, Aranda A. MicroRNAS 424 and 503 are mediators of the anti-proliferative and anti-invasive action of the thyroid hormone receptor beta. Oncotarget. 2014;5:2918–33.CrossRefPubMedPubMedCentral

20.

Peng Y, Liu YM, Li LC, Wang LL, Wu XL. MicroRNA-503 inhibits gastric cancer cell growth and epithelial-to-mesenchymal transition. Oncol Lett. 2014;7:1233–8.PubMedPubMedCentral

21.

Valinezhad Orang A, Safaralizadeh R. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. 2014;2014:970607.

22.

Vidaurre S, Fitzpatrick C, Burzio VA, Briones M, Villota C, Villegas J, et al. Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy. J Biol Chem. 2014;289:27182–98.CrossRefPubMedPubMedCentral

23.

Li C, Xiong Q, Zhang J, Ge F, Bi LJ. Quantitative proteomic strategies for the identification of microRNA targets. Expert Rev Proteomics. 2012;9:549–59.CrossRefPubMed

24.

Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget 2015.

25.

Liang H, Liu M, Yan X, Zhou Y, Wang W, Wang X, et al. miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4. J Biol Chem. 2015;290:926–40.CrossRefPubMed

26.

Jiang J, Lv X, Fan L, Huang G, Zhan Y, Wang M, et al. MicroRNA-27b suppresses growth and invasion of NSCLC cells by targeting Sp1. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35:10019–23.CrossRef

27.

Yang Y, Liu L, Zhang Y, Guan H, Wu J, Zhu X, et al. MiR-503 targets PI3K p85 and IKK-beta and suppresses progression of non-small cell lung cancer. Int J Cancer J Int du Cancer. 2014;135:1531–42.CrossRef

28.

Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.CrossRefPubMed

29.

Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007;98:629–35.CrossRefPubMed

30.

Schaal C, Pillai S, Chellappan SP. The Rb-E2F transcriptional regulatory pathway in tumor angiogenesis and metastasis. Adv Cancer Res. 2014;121:147–82.CrossRefPubMed

Titel: MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression
verfasst von: Jianting Long
Caiwen Ou
Haoming Xia
Yifan Zhu
Dayue Liu
Publikationsdatum: 01.11.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 11/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3623-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2015

MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expressions

Long non-coding RNA HOTTIP is correlated with progression and prognosis in tongue squamous cell carcinoma

Gab1 regulates proliferation and migration through the PI3K/Akt signaling pathway in intrahepatic cholangiocarcinoma

Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair

Expression of long noncoding RNA-HOX transcript antisense intergenic RNA in oral squamous cell carcinoma and effect on cell growth

MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-κB pathway

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie